SE8004002L
(sv)
*
|
1980-05-29 |
1981-11-30 |
Arvidsson Folke Lars Erik |
Terapeutiskt anvendbara tetralinderivat
|
US4839104A
(en)
*
|
1987-06-11 |
1989-06-13 |
Pfizer, Inc. |
Process for preparing sertraline intermediates
|
US4777288A
(en)
*
|
1987-06-11 |
1988-10-11 |
Pfizer Inc. |
Process for preparing a 4,4-diphenylbutanoic acid derivative
|
FR2623802B1
(fr)
*
|
1987-11-26 |
1990-05-04 |
Lucien Laboratoires |
Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
|
US4855500A
(en)
*
|
1988-05-04 |
1989-08-08 |
Pfizer Inc. |
Process for preparing a ketimine
|
FR2632633B1
(fr)
*
|
1988-06-08 |
1991-04-05 |
Delalande Sa |
Procede de preparation de 4-aryl-1-tetralones
|
US4981870A
(en)
*
|
1989-03-07 |
1991-01-01 |
Pfizer Inc. |
Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
|
EP0415612B1
(en)
*
|
1989-08-30 |
1993-11-10 |
Pfizer Inc. |
Use of sertraline for the treatment of chemical dependencies
|
US4940731A
(en)
*
|
1989-08-30 |
1990-07-10 |
Pfizer Inc. |
Method of treating premature ejaculation using sertraline
|
US5130338A
(en)
*
|
1989-08-30 |
1992-07-14 |
Pfizer Inc. |
Method of treating chemical dependencies using sertraline
|
US4962128A
(en)
*
|
1989-11-02 |
1990-10-09 |
Pfizer Inc. |
Method of treating anxiety-related disorders using sertraline
|
FR2665443B1
(fr)
*
|
1990-08-03 |
1992-11-06 |
Lucien Laboratoires |
Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
|
US5082970A
(en)
*
|
1991-03-06 |
1992-01-21 |
Pfizer Inc. |
Process for recycling amine isomer
|
GB9114948D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
GB9114947D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline
|
US5196607A
(en)
*
|
1992-02-14 |
1993-03-23 |
Pfizer Inc. |
Process for preparing ketone enantiomer
|
US5248699A
(en)
*
|
1992-08-13 |
1993-09-28 |
Pfizer Inc. |
Sertraline polymorph
|
US5288916A
(en)
|
1993-03-25 |
1994-02-22 |
Bend Research, Inc. |
Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
|
DK0724552T3
(da)
*
|
1993-11-30 |
1997-12-22 |
Pfizer |
Fremgangsmåde til fremstilling af chiralt tetralon
|
US5597826A
(en)
|
1994-09-14 |
1997-01-28 |
Pfizer Inc. |
Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
|
US6410794B1
(en)
|
1994-12-16 |
2002-06-25 |
Uop Llc |
Process for preparation of pharmaceutically desired chiral tetralone from tetralones
|
US6455736B1
(en)
|
1994-12-16 |
2002-09-24 |
Uop Llc |
Process for preparation of pharmaceutically desired sertraline and sertraline analogs
|
WO1996041633A1
(en)
*
|
1995-06-08 |
1996-12-27 |
Eli Lilly And Company |
Methods of treating cold and allergic rhinitis
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
EP0759299B1
(en)
*
|
1995-08-16 |
2000-04-26 |
Eli Lilly And Company |
Potentiation of serotonin response
|
US5734083A
(en)
*
|
1996-05-17 |
1998-03-31 |
Torcan Chemical Ltd. |
Sertraline polymorph
|
HU222341B1
(hu)
*
|
1996-12-18 |
2003-06-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
|
TW403740B
(en)
*
|
1997-06-10 |
2000-09-01 |
Novartis Ag |
Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
|
US20030133974A1
(en)
*
|
1997-07-01 |
2003-07-17 |
Curatolo William John |
Encapsulated solution dosage forms of sertraline
|
US20040208926A1
(en)
*
|
1997-07-01 |
2004-10-21 |
Pfizer Inc |
Solubilized sertraline compositions
|
AU739261B2
(en)
|
1997-07-01 |
2001-10-11 |
Pfizer Inc. |
Sertraline salts and sustained-release dosage forms of sertraline
|
DE69713353D1
(de)
*
|
1997-12-11 |
2002-07-18 |
Torcan Chemical Ltd |
Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
|
IN191358B
(uk)
*
|
1998-01-16 |
2003-11-29 |
Pfizer Prod Inc |
|
WO1999046233A1
(fr)
*
|
1998-03-09 |
1999-09-16 |
Sumika Fine Chemicals Co., Ltd. |
Derives de l'alcool benzylique
|
WO1999047486A1
(en)
|
1998-03-18 |
1999-09-23 |
Ciba Specialty Chemicals Holding Inc. |
Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
|
FR2777000B1
(fr)
*
|
1998-04-01 |
2002-09-27 |
Catalys |
Procede de preparation de la sertraline racemique
|
PT957099E
(pt)
*
|
1998-04-15 |
2003-02-28 |
Pfizer Prod Inc |
Carboxamidas heterociclicas
|
US6054614A
(en)
*
|
1998-04-23 |
2000-04-25 |
Ciba Specialty Chemicals Corporation |
Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
|
HU226423B1
(en)
*
|
1998-05-05 |
2008-12-29 |
Egis Gyogyszergyar Nyrt |
Process for producing a 1(2h)-naphtalene-1-ylidene derivative
|
HU226424B1
(en)
*
|
1998-05-05 |
2008-12-29 |
Egis Gyogyszergyar Nyrt |
Process for producing enantiomer mixture for preparation of sertraline
|
IN182588B
(uk)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
DE19830201A1
(de)
*
|
1998-07-07 |
2000-01-13 |
Boehringer Ingelheim Pharma |
Mittel mit antidepressiver Wirkung
|
EE04868B1
(et)
*
|
1998-10-13 |
2007-08-15 |
Pfizer Products Inc. |
Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis
|
US6727283B2
(en)
|
1998-10-13 |
2004-04-27 |
Pfizer Inc. |
Sertraline oral concentrate
|
IL132500A0
(en)
|
1998-10-29 |
2001-03-19 |
Pfizer Prod Inc |
Stereoselective microbial reduction of a racemic tetralone
|
WO2000025598A1
(en)
*
|
1998-11-03 |
2000-05-11 |
Dandy A/S |
Sucrose fatty acid esters for use as increased release of active ingredients
|
US6518284B2
(en)
*
|
1998-11-18 |
2003-02-11 |
Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. |
4-substituted piperidines
|
EP1632473A1
(en)
*
|
1998-11-27 |
2006-03-08 |
Teva Pharmaceutical Industries Ltd |
Sertraline hydrochloride polymorphs
|
US6500987B1
(en)
*
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
EP1133459B1
(en)
*
|
1998-11-27 |
2006-01-11 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride form v
|
EP1157002B1
(en)
*
|
1999-03-01 |
2005-08-10 |
Pfizer Limited |
1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
US6593496B1
(en)
*
|
1999-06-09 |
2003-07-15 |
Pfizer Inc |
Process for preparing sertraline from chiral tetralone
|
WO2001009080A1
(en)
*
|
1999-07-29 |
2001-02-08 |
Ciba Specialty Chemicals Holding Inc. |
Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
|
US6495721B1
(en)
|
1999-08-09 |
2002-12-17 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride Form II and methods for the preparation thereof
|
IN185109B
(uk)
*
|
1999-09-01 |
2000-11-18 |
Torrent Pharmaceuticals Ltd |
|
DK174219B1
(da)
*
|
1999-10-27 |
2002-09-30 |
Gea Farmaceutisk Fabrik As |
Forbedret syntese af racemisk sertralin
|
TWI260315B
(en)
|
1999-10-29 |
2006-08-21 |
Ciba Sc Holding Ag |
Polymorphic forms of sertraline hydrochloride
|
US20050119351A1
(en)
*
|
1999-10-29 |
2005-06-02 |
Van Der Schaaf Paul A. |
Polymorphic forms of sertraline hydrochloride
|
US7442838B2
(en)
*
|
1999-10-29 |
2008-10-28 |
Ciba Specialty Chemicals Corp. |
Polymorphic forms of sertraline hydrochloride
|
CN1250522C
(zh)
|
1999-11-16 |
2006-04-12 |
西巴特殊化学品控股有限公司 |
制备酮亚胺的方法
|
US6806386B1
(en)
*
|
1999-11-16 |
2004-10-19 |
Ciba Specialty Chemicals Corporation |
Process for the preparation of ketimines
|
US6380200B1
(en)
|
1999-12-07 |
2002-04-30 |
Pfizer, Inc. |
Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
|
ATE354358T1
(de)
*
|
1999-12-21 |
2007-03-15 |
Teva Pharma |
Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
|
WO2001047498A2
(en)
|
1999-12-23 |
2001-07-05 |
Pfizer Products Inc. |
Hydrogel-driven layered drug dosage form comprising sertraline
|
IN187170B
(uk)
|
2000-01-04 |
2002-02-23 |
Sun Pharmaceutical Ind Ltd |
|
JP2003527359A
(ja)
*
|
2000-03-14 |
2003-09-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
(+)−シス−セルトラリンの製造のための新規方法
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
IN192343B
(uk)
*
|
2000-05-26 |
2004-04-10 |
Ranbaxy Lab Ltd |
|
US6630504B2
(en)
|
2000-08-31 |
2003-10-07 |
Pfizer Inc. |
Phenoxyphenylheterocyclyl derivatives as SSRIs
|
EP1184372B1
(en)
*
|
2000-08-31 |
2006-04-26 |
Pfizer Limited |
Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs)
|
US6482440B2
(en)
|
2000-09-21 |
2002-11-19 |
Phase 2 Discovery, Inc. |
Long acting antidepressant microparticles
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
EP1397343A1
(en)
*
|
2001-05-31 |
2004-03-17 |
Orion Corporation Fermion |
Process for preparing sertraline hydrochloride polymorphic form ii
|
EP1401800A1
(en)
*
|
2001-06-15 |
2004-03-31 |
Orion Corporation Fermion |
A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
|
US6723878B2
(en)
|
2001-06-15 |
2004-04-20 |
Orion Corporation Fermion |
Method for preparing sertraline
|
EP1434763B1
(en)
*
|
2001-10-12 |
2018-01-17 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl vasopressin v1a antagonists
|
JP4625637B2
(ja)
|
2002-02-22 |
2011-02-02 |
シャイア エルエルシー |
活性物質送達系及び活性物質を保護し投与する方法
|
CA2483569A1
(en)
*
|
2002-04-29 |
2003-11-13 |
Tamar Nidam |
Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
|
AU2003254475A1
(en)
*
|
2002-07-29 |
2004-02-16 |
Cipla Limited |
Sertraline
|
WO2004041773A1
(en)
*
|
2002-11-07 |
2004-05-21 |
Sunil Sadanand Nadkarni |
Process for preparation of polymorphic form of sertraline hydrochloride
|
US20040131672A1
(en)
*
|
2003-01-07 |
2004-07-08 |
Nilobon Podhipleux |
Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
WO2004087732A2
(en)
*
|
2003-03-11 |
2004-10-14 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine
|
TW200503991A
(en)
*
|
2003-04-14 |
2005-02-01 |
Teva Pharma |
Hydrogenation of imine intermediates of sertraline with catalysts
|
EP1626950A4
(en)
*
|
2003-05-23 |
2007-05-23 |
Transform Pharmaceuticals Inc |
SERTRALINZUSAMMENSETZUNGEN
|
US20050070577A1
(en)
*
|
2003-07-03 |
2005-03-31 |
Pfizer Inc. |
Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
WO2005012225A1
(en)
*
|
2003-07-15 |
2005-02-10 |
Recordati Industria Chimica E Farmaceutica S.P.A. |
Methods for preparing sertraline hydrochloride polymorphs
|
WO2005012224A1
(en)
*
|
2003-07-15 |
2005-02-10 |
Recordati Industria Chimica E Farmaceutica S.P.A. |
Sertraline hydrochloride form ii and methods for the preparation thereof
|
HU227495B1
(en)
*
|
2003-07-21 |
2011-07-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Process for producing of imine intermediate
|
US7262327B2
(en)
*
|
2003-09-05 |
2007-08-28 |
Teva Pharmaceutical Industries Ltd. |
Recycling process for preparing sertraline
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
EP1675582A1
(en)
*
|
2003-09-12 |
2006-07-05 |
Warner-Lambert Company LLC |
Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
|
KR101151653B1
(ko)
*
|
2003-09-17 |
2012-06-28 |
얀센 파마슈티카 엔.브이. |
융합된 헤테로사이클릭 화합물
|
US7893300B2
(en)
*
|
2003-11-04 |
2011-02-22 |
Cipla Limited |
Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
|
WO2005051488A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Combination of dopamine agonists and monoamine reuptake inhibitors
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
EP2343073A3
(en)
|
2003-12-11 |
2011-10-12 |
Sepracor Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
US20050250738A1
(en)
*
|
2004-05-06 |
2005-11-10 |
Mosher Gerold L |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
PE20060437A1
(es)
|
2004-06-18 |
2006-06-08 |
Novartis Ag |
COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
TW200640836A
(en)
*
|
2005-02-23 |
2006-12-01 |
Teva Pharma |
Processes for preparing sertraline
|
US9597314B2
(en)
|
2005-03-22 |
2017-03-21 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
JP2006265169A
(ja)
*
|
2005-03-24 |
2006-10-05 |
Tokuyama Corp |
アルキリデンコハク酸化合物の製造方法
|
GB0507090D0
(en)
*
|
2005-04-07 |
2005-05-11 |
Sandoz Ag |
Process for preparing polymorphic form ll of sertraline hydrochloride
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GT200600164A
(es)
|
2005-04-22 |
2007-03-14 |
|
Derivados de dihidrobenzofuranos y usos de los mismos
|
EP1871358A1
(en)
|
2005-04-22 |
2008-01-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
|
US20060252825A1
(en)
*
|
2005-04-22 |
2006-11-09 |
Wyeth |
Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
|
US7365095B2
(en)
*
|
2005-04-22 |
2008-04-29 |
Wyeth |
Chromane and chromene derivatives and uses thereof
|
GT200600165A
(es)
*
|
2005-04-22 |
2007-03-14 |
|
Derivados dihidrobenzofuranos y usos de los mismos
|
CA2576097C
(en)
*
|
2005-06-03 |
2009-10-27 |
Hetero Drugs Limited |
A highly stereoselective synthesis of sertraline
|
US20070100165A1
(en)
*
|
2005-06-09 |
2007-05-03 |
Ronen Borochovitz |
Process for preparation of sertraline hydrochloride form I
|
US7884136B2
(en)
*
|
2005-06-27 |
2011-02-08 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
WO2007008758A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
KR101523776B1
(ko)
|
2005-07-19 |
2015-05-28 |
아제반 파마슈티칼스, 인코퍼레이티드 |
베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
|
US7598255B2
(en)
*
|
2005-08-04 |
2009-10-06 |
Janssen Pharmaceutica Nv |
Pyrimidine compounds as serotonin receptor modulators
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
CN101426372A
(zh)
*
|
2006-01-06 |
2009-05-06 |
塞普拉柯公司 |
基于四氢萘酮的单胺再摄取抑制剂
|
US20070213562A1
(en)
*
|
2006-01-23 |
2007-09-13 |
Ami Zoran |
Recycling process for preparing sertraline
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CA2644662A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
WO2007119247A2
(en)
*
|
2006-04-17 |
2007-10-25 |
Unichem Laboratories Limited |
Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride)
|
TR200808115T1
(tr)
*
|
2006-04-28 |
2009-03-23 |
Sandoz Ag |
4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
US7518019B2
(en)
*
|
2006-06-01 |
2009-04-14 |
Hetero Drugs Limited |
Processes for preparing sertraline hydrochloride crystalline forms
|
US20100279990A1
(en)
*
|
2006-06-13 |
2010-11-04 |
Ramot At Tel-Aviv University Ltd. |
Antiproliferative compounds, compositions and methods of use
|
US7893053B2
(en)
*
|
2006-06-16 |
2011-02-22 |
Theracos, Inc. |
Treating psychological conditions using muscarinic receptor M1 antagonists
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
US20060257475A1
(en)
*
|
2006-08-17 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Stable Sertraline Hydrochloride Formulation and Method
|
KR20090064418A
(ko)
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
WO2008034032A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Azevan Pharmaceuticals, Inc. |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
FR2909376A1
(fr)
*
|
2006-11-30 |
2008-06-06 |
Cerep Sa |
Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
EP2125017A2
(en)
*
|
2007-01-11 |
2009-12-02 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
CA2594198A1
(en)
*
|
2007-07-20 |
2009-01-20 |
Apotex Pharmachem Inc. |
A novel process for the preparation of sertraline hydrochloride form ii
|
US20090062399A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sertraline
|
US8461389B2
(en)
|
2008-04-18 |
2013-06-11 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
EP2288345B1
(en)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US9260413B2
(en)
*
|
2010-03-04 |
2016-02-16 |
Merck Sharp & Dohme Corp. |
Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
|
EP2380595A1
(en)
|
2010-04-19 |
2011-10-26 |
Nlife Therapeutics S.L. |
Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
|
WO2011163231A2
(en)
|
2010-06-21 |
2011-12-29 |
Theracos, Inc. |
Combination therapy for the treatment of diabetes
|
CA2804001C
(en)
|
2010-07-01 |
2021-02-09 |
Azevan Pharmaceuticals, Inc. |
Methods for treating post traumatic stress disorder
|
JP2014508187A
(ja)
|
2011-03-17 |
2014-04-03 |
ルピン・リミテッド |
選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
|
KR101340270B1
(ko)
*
|
2011-11-10 |
2013-12-10 |
보령제약 주식회사 |
(+)-시스-서트랄린의 선택적인 제조방법
|
NZ703537A
(en)
*
|
2012-10-18 |
2018-06-29 |
Hoffmann La Roche |
Ethynyl derivatives
|
BR112016022575A2
(pt)
|
2014-03-28 |
2017-08-15 |
Azevan Pharmaceuticals Inc |
Composições e métodos para o tratamento de doenças neurodegenerativas
|
WO2015193921A1
(en)
|
2014-06-20 |
2015-12-23 |
Council Of Scientific And Industrial Research |
An organocatalytic asymmetric synthesis of antidepressants
|
WO2016023831A1
(en)
*
|
2014-08-11 |
2016-02-18 |
Hydra Biosciences, Inc. |
Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
|
JP6573968B2
(ja)
*
|
2014-08-11 |
2019-09-11 |
ハイドラ バイオサイエンシズ インコーポレイテッドHydra Biosciences,Inc. |
TRPC5調節因子としての、精神神経障害の処置のためのチエノおよびフロ[2,3−d]ピリミジン−2,4[1H,3H]−ジオン誘導体
|
EP3180337B1
(en)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
|
EP3180340B1
(en)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
|
EP3352905B1
(en)
|
2015-09-21 |
2022-12-07 |
S.C. Johnson & Son, Inc. |
System for mixing and dispensing
|
CN111295373A
(zh)
|
2017-09-15 |
2020-06-16 |
阿泽凡药物公司 |
用于治疗脑损伤的组合物和方法
|
WO2020043716A1
(en)
|
2018-08-27 |
2020-03-05 |
Katholieke Universiteit Leuven |
Pharmacological targeting of de novo serine/glycine synthesis
|